Skip to main content
. 2023 May 12;26(3):379–387. doi: 10.1007/s00737-023-01325-0

Table 1.

Demographics, psychosocial, and clinical profile of women with SMI

Patient Age (years) Country of birth #Parity Education level attained Psychiatric diagnosis Medication
P1 31 Australia 1 Not completed Bipolar type 1

lithium 450 mg

lamotrigine 50 mg, quetiapine 50 mg

P2 29 Australia 2 Year 12 Bipolar type 1

lithium 1250 mg

quetiapine 200 mg

P3 33 Australia 1 Tertiary Bipolar type 2

lithium 900 mg

duloxetine 120 mg

escitalopram 20 mg

lamotrigine 200 mg

quetiapine XR 250 mg

P4 36 Australia 1 Tertiary Bipolar type 1 aripiprazole 10 mg
P5 30 Australia 2 Year 12 Bipolar type 2

Fluoxetine 40 mg

lamotrigine 400 mg

quetiapine 100 mg

P6 41 Australia 2 Tertiary Bipolar type 1

lamotrigine 200 mg

escitalopram 10 mg olanzapine 2.5 mg

P7 34 Australia 6 Not completed Bipolar type 2

Lithium 450 mg

Olanzapine 5 mg mirtazapine 30 mg

P8 28 Afghanistan 1 Year 12 Schizophrenia olanzapine 5 mg
P9 33 Australia 3 Tertiary Bipolar type 2 quetiapine XR 300 mg
P10 37 Australia 1 Trade certificate Bipolar type 1

lamotrigine 300 mg

sertraline 100 mg

P11 33 Australia 2 Trade certificate Schizophrenia

aripiprazole 10 mg

olanzapine 10 mg

P12 31 Ethiopia 2 Trade certificate Schizophrenia aripiprazole depo 400 mg

#parity = births completed